相关实验视频
Updated: Jun 22, 2025

10:29
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
1.3K
非信号外细胞间隔器调节CAR T细胞的瘤抗原选择性
Kelly T Kennewick1, Yukiko Yamaguchi1, Jackson Gibson1
1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA.
Molecular therapy. Oncology
|June 28, 2024
概括
优化化学抗原受体 (CAR) T细胞治疗固体瘤包括调整细胞外间隔器. 间隔器设计影响CAR T细胞选择性,增强对抗高抗原瘤的疗效,同时保护健康组织.
科学领域:
- 细胞免疫疗法细胞免疫疗法
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 化学抗原受体 (CAR) T细胞疗法对固体瘤有希望,但面临着诸如瘤外瘤毒性等挑战.
- 优化CAR结构的瘤抗原选择性和安全性对于固体瘤治疗的临床成功至关重要.
研究的目的:
- 评估各种非信号外细胞间隔器对CAR T细胞选择性和有效性的影响.
- 为了研究间隔器的长度和结构如何影响CAR T细胞针对不同抗原密度的瘤细胞的向.
主要方法:
- 开发针对前列腺干细胞抗原 (PSCA) 和HER2的CAR T细胞疗法.
- 在CAR结构中对不同非信号外细胞间隔器设计的系统评估.
- 评估CAR T细胞根据抗原密度选择性向瘤细胞的能力.
主要成果:
- 细胞外间隙的长度和结构显著影响CAR T细胞瘤抗原的选择性.
- 具有优化间隔器的CAR T细胞表现出更好的向高抗原密度瘤细胞.
- 间隔器的修改可以节省抗原密度低的细胞,从而有可能减少瘤外毒性.
结论:
- 间隔器设计是开发安全有效的CAR T细胞治疗固体瘤的关键因素.
- 调整细胞外间隔器增强了CAR T细胞的特异性,改善了固体瘤治疗的治疗窗口.
- 这项研究为CAR构造设计提供了宝贵的见解,以推进固体瘤免疫治疗.
相关概念视频
T Cell Activation and Clonal Selection
699
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
699
Tumor Immunotherapy
510
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510

